title: Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge.
abstract: Anti-erythropoietin (EPO)-induced pure red cell aplasia (PRCA) is an uncommon, potentially life-threatening condition in which the bone marrow stops manufacturing red blood cells. In the past few years, reports of drug-induced, anti-EPO antibody-mediated PRCA have increased substantially, with most cases attributed to the use of one erythropoiesis-stimulating protein, Eprex. A literature review was undertaken to document the reports of drug-induced PRCA, with all drugs and drug regimens. The sudden increase in reports of antibody-mediated PRCA is discussed.
authors.affiliation: Amgen Inc, One Amgen Center Drive, M/S 24-1-C, Thousand Oaks, CA 91320-1799, USA.
authors.forename: Ralph
authors.initials: R
authors.lastname: Smalling
authors.forename: MaryAnn
authors.initials: M
authors.lastname: Foote
authors.forename: Graham
authors.initials: G
authors.lastname: Molineux
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Swanson
authors.forename: Steve
authors.initials: S
authors.lastname: Elliott
mesh_terms: D000906:Antibodies / Q000276:immunology*; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000276:immunology*
chemical_list: D000906:Antibodies; D007155:Immunologic Factors; D011994:Recombinant Proteins; D004921:Erythropoietin